Mayar M. Mussa
FDA investigator
Appears on 1 document from 2026, mostly at sites in New Jersey. Most often cites postmarketing reporting of adverse drug experiences (21 CFR 314.80(b)).
- 1
- Documents on file
- 1.0
- Observations per 483
- 2026
- First seen
- 2026
- Most recent
What they cite most
From 1 observations- 21 CFR 314.80(b)Postmarketing reporting of adverse drug experiences1
Activity by year
2026: 1
Where
New Jersey 1
Is Mayar M. Mussa coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
1 document, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2026-02-12 | 483 Waylis Therapeutics LLCFeb 12, 2026 · Rahway, New Jersey | Rahway, New Jersey | 1 |
About this profile
What does Mayar M. Mussa inspect?
Mayar M. Mussa appears on 1 document on file covering 1 site, mostly in New Jersey.
What do they cite most often?
21 CFR 314.80(b) (postmarketing reporting of adverse drug experiences).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Mayar M. Mussa is dated Feb 12, 2026.